U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H20FN3O3
Molecular Weight 357.3788
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DANOFLOXACIN

SMILES

CN1C[C@@H]2C[C@H]1CN2C3=CC4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=QMLVECGLEOSESV-RYUDHWBXSA-N
InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H20FN3O3
Molecular Weight 357.3788
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Danofloxacin is a quinolone antibacterial agent for veterinary medicine. The drug is approved by FDA for the treatment of bovine infectious respiratory disease under the name Advocin (mesylate salt). Danofloxacin exerts its action by inhibiting bacterial DNA gyrase.

Originator

Curator's Comment: # Pfizer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ADVOCIN

Approved Use

For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica and Pasteurella multocida and for the control of BRD in beef cattle at high risk of developing BRD associated with Mannheimia haemolytica and Pasteurella multocida.

Launch Date

2011
PubMed

PubMed

TitleDatePubMed
Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration.
1999 Aug
Pharmacokinetic and pharmacodynamic profiles of danofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella) haemolytica.
2002 Sep
Effect of Danofloxacin on Reactive Oxygen Species Production, Lipid Peroxidation and Antioxidant Enzyme Activities in Kidney Tubular Epithelial Cell Line, LLC-PK1.
2013 Dec
Toxic effects of methylmercury, arsanilic acid and danofloxacin on the differentiation of mouse embryonic stem cells into neural cells.
2014
Patents

Sample Use Guides

Administered by subcutaneous injection at either 8 mg per kilogram of body weight once or 6 mg per kilogram of body weight with treatment repeated once approximately 48 hours following the first injection.
Route of Administration: Other
Danofloxacin minimum inhibitory concentration values (MIC90) were 0.06 ug/mL for both Mannheimia haemolytica and Pasteurella multocida.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:17:14 GMT 2023
Edited
by admin
on Fri Dec 15 16:17:14 GMT 2023
Record UNII
24CU1YS91D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DANOFLOXACIN
GREEN BOOK   INN   MI  
INN  
Official Name English
1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-7-((1S,4S)-5-METHYL-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID
Systematic Name English
A180
Brand Name English
DANOFLOXACIN [GREEN BOOK]
Common Name English
DANOFLOXACIN [MI]
Common Name English
3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-7-(5-METHYL-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)-4-OXO-, (1S)-
Common Name English
danofloxacin [INN]
Common Name English
ADVOCIN
Brand Name English
Classification Tree Code System Code
CFR 21 CFR 556.169
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
CFR 21 CFR 522.522
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
WHO-VATC QJ01MA92
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
NCI_THESAURUS C795
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
Code System Code Type Description
SMS_ID
100000083438
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
EVMPD
SUB06901MIG
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
DRUG BANK
DB11393
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
WIKIPEDIA
DANOFLOXACIN
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
CAS
112398-08-0
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
EPA CompTox
DTXSID0046432
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
INN
6424
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
DAILYMED
24CU1YS91D
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
NCI_THESAURUS
C72731
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
PUBCHEM
71335
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
FDA UNII
24CU1YS91D
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
RXCUI
1358488
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m4082
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL157548
Created by admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY